文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

胰腺癌耐药中的微小RNA:机制与治疗潜力

MicroRNAs in pancreatic cancer drug resistance: mechanisms and therapeutic potential.

作者信息

Dong Fangying, Zhou Jing, Wu Yijie, Gao Zhaofeng, Li Weiwei, Song Zhengwei

机构信息

Emergency Department, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.

Department of Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.

出版信息

Front Cell Dev Biol. 2025 Jan 15;12:1499111. doi: 10.3389/fcell.2024.1499111. eCollection 2024.


DOI:10.3389/fcell.2024.1499111
PMID:39882259
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11774998/
Abstract

Pancreatic cancer (PC) remains one of the most lethal malignancies, primarily due to its intrinsic resistance to conventional therapies. MicroRNAs (miRNAs), key regulators of gene expression, have been identified as crucial modulators of drug resistance mechanisms in this cancer type. This review synthesizes recent advancements in our understanding of how miRNAs influence treatment efficacy in PC. We have thoroughly summarized and discussed the complex role of miRNA in mediating drug resistance in PC treatment. By highlighting specific miRNAs that are implicated in drug resistance pathways, we provide insights into their functional mechanisms and interactions with key molecular targets. We also explore the potential of miRNA-based strategies as novel therapeutic approaches and diagnostic tools to overcome resistance and improve patient outcomes. Despite promising developments, challenges such as specificity, stability, and effective delivery of miRNA-based therapeutics remain. This review aims to offer a critical perspective on current research and propose future directions for leveraging miRNA-based interventions in the fight against PC.

摘要

胰腺癌(PC)仍然是最致命的恶性肿瘤之一,主要是由于其对传统疗法具有内在抗性。微小RNA(miRNA)作为基因表达的关键调节因子,已被确定为这种癌症类型中耐药机制的关键调节因子。本综述综合了我们对miRNA如何影响胰腺癌治疗效果的最新认识进展。我们全面总结并讨论了miRNA在介导胰腺癌治疗耐药性中的复杂作用。通过强调与耐药途径相关的特定miRNA,我们深入了解了它们的功能机制以及与关键分子靶点的相互作用。我们还探讨了基于miRNA的策略作为克服耐药性和改善患者预后的新型治疗方法和诊断工具的潜力。尽管有前景良好的进展,但基于miRNA的治疗方法的特异性、稳定性和有效递送等挑战仍然存在。本综述旨在对当前研究提供批判性观点,并为在抗击胰腺癌中利用基于miRNA的干预措施提出未来方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d47/11774998/11de8bf2afd6/fcell-12-1499111-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d47/11774998/7b3d3e303540/fcell-12-1499111-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d47/11774998/11de8bf2afd6/fcell-12-1499111-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d47/11774998/7b3d3e303540/fcell-12-1499111-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d47/11774998/11de8bf2afd6/fcell-12-1499111-g002.jpg

相似文献

[1]
MicroRNAs in pancreatic cancer drug resistance: mechanisms and therapeutic potential.

Front Cell Dev Biol. 2025-1-15

[2]
Exosomal miRNA-based theranostics in cervical cancer: bridging diagnostics and therapy.

Med Oncol. 2025-5-4

[3]
Flavonoids as modulators of miRNA expression in pancreatic cancer: Pathways, Mechanisms, And Therapeutic Potential.

Biomed Pharmacother. 2024-10

[4]
Association between microRNAs and chemoresistance in pancreatic cancer: Current knowledge, new insights, and forthcoming perspectives.

Pathol Res Pract. 2022-8

[5]
MicroRNAs as Promising Therapeutic Agents Against Prostate Cancer Resistant to Castration-Where Are We Now?

Pharmaceutics. 2024-10-22

[6]
Functional and Potential Therapeutic Implication of MicroRNAs in Pancreatic Cancer.

Int J Mol Sci. 2023-12-15

[7]
MicroRNAs as promising biomarkers and potential therapeutic agents in breast cancer management: a comprehensive review.

Ann Med Surg (Lond). 2024-4-22

[8]
MicroRNAs: emerging biomarkers and therapeutic targets in pancreatic cancer.

Front Mol Biosci. 2024-9-3

[9]
Development of microRNA-based therapy for pancreatic cancer.

J Pancreatol. 2019-12

[10]
MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers.

J Cell Mol Med. 2013-9-23

本文引用的文献

[1]
Cancer-associated fibroblast-derived exosome Leptin promotes malignant biological lineage in pancreatic ductal adenocarcinoma by regulating ABL2 via miR-224-3p.

Mol Biol Rep. 2024-9-19

[2]
Resistance to gemcitabine is mediated by the circ_0036627/miR-145/S100A16 axis in pancreatic cancer.

J Cell Mol Med. 2024-6

[3]
CAFs-Associated Genes (CAFGs) in Pancreatic Ductal Adenocarcinoma (PDAC) and Novel Therapeutic Strategy.

Int J Mol Sci. 2024-5-30

[4]
Current and future immunotherapeutic approaches in pancreatic cancer treatment.

J Hematol Oncol. 2024-6-4

[5]
Pancreatic cancer cells hijack tumor suppressive microRNA-26a to promote radioresistance and potentiate tumor repopulation.

Heliyon. 2024-5-15

[6]
MKLN1-AS promotes pancreatic cancer progression as a crucial downstream mediator of HIF-1α through miR-185-5p/TEAD1 pathway.

Cell Biol Toxicol. 2024-5-13

[7]
MicroRNAs in Pancreatic Cancer: Advances in Biomarker Discovery and Therapeutic Implications.

Int J Mol Sci. 2024-3-31

[8]
Meta-analysis of adjuvant chemotherapy versus no adjuvant chemotherapy for resected stage I pancreatic cancer.

Surgery. 2024-6

[9]
Dysregulation of the circ_0087502/miR-1179/TGFBR2 pathway supports gemcitabine resistance in pancreatic cancer.

Cancer Biol Ther. 2023-12-31

[10]
LncRNA BCCE4 Genetically Enhances the PD-L1/PD-1 Interaction in Smoking-Related Bladder Cancer by Modulating miR-328-3p-USP18 Signaling.

Adv Sci (Weinh). 2023-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索